Date:	7/10/2024	
Your Name:	Adrian Nickson	
Manuscript Title:	MEDI1814 selectively reduces free A242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Amanda D. Dudley
Manuscript Title:	MEDI1814 selectively reduces free A242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: Description of the initial planning AstraZeneca AstraZeneca AstraZeneca AstraZeneca AstraZeneca	of the work Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Andy Billinton	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Anna Bogstedt	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	c
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Employee
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Christopher Lloyd	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	charges, etc.) No time limit for this item.		
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not	None AstraZeneca	Employee
	indicated in item #1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Craig Shering
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	this item.		
		Time frame: past 36 month	s
2	Grants or contracts from		
	any entity (if not indicated in item	AstraZeneca	Employee
	#1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	David Lowne
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Eva Lindqvist	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Fanni Natanegara	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Eli Lilly AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Eli Lilly	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024
Your Name:	Fraser Welsh
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	this item.		
		Time frame: past 36 month	s
2	Grants or contracts from		
	any entity (if not indicated in item	AstraZeneca	Employee
	#1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	Other financial or non-financial	None	
	interests		
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	ent:
$[\boxtimes]$	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	7/10/2024
Your Name:	Iain P. Chessell
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	Other financial or non-financial	None	
	interests		
Plea	se place an "X" nex	t to the following statement to indicate your agreeme	ent:
$[\boxtimes]$	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	7/10/2024
Your Name:	Jeffrey L. Dage
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: None Eli Lilly AstraZeneca AstraZeneca	of the work Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	D None	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Eisai	Consultant of advisory board
		Abbvie	Consultant of advisory board
		Genotix Biotechnologies Inc	Consultant of advisory board
		Gates Ventures	Consultant of advisory board
		Karuna Therapeutics	Consultant of advisory board
		AlzPath Inc	Consultant of advisory board
		Cognito Therapeutics, Inc.	Consultant of advisory board
5	Payment or honoraria for	None	
	lectures,	Eli Lilly and Company	Speaker fees
	presentations,		
	speakers		
	bureaus,		
	manuscript		
	writing or educational		
	events		
6	Payment for	⊠ None	
Ŭ	expert testimony		
	, ,		
7	Support for	⊠ None	
	attending		
	meetings and/or		
	travel		
8	Patents planned, issued or		
	pending	Eli Lilly and Company	Patents
9	Participation on	None	
	a Data Safety		
	Monitoring Board or		
	Advisory Board		
10	Leadership or	⊠ None	
	fiduciary role in other board,		
	society,		
	committee or		
	advocacy group,		
	paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	□ None	
		Genotix Biotechnologies	Stock/stock options
		AlzPath Inc	Stock/stock options
		Monument Biosciences	Stock/stock options
		Eli Lilly and Company	Stock/stock options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing,		
	gifts or other services		
13	Other financial or non-financial	□ None	
	interests	ADx Neurosciences	Research support
		Fujirebio	Research support
		AlzPath Inc	Research support
		Roche Diagnostics	Research support
		Eli Lilly and Company	Research support

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	7/10/2024
Your Name:	John R. Sims
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: None Eli Lilly AstraZeneca AstraZeneca	of the work Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	D None	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024
Your Name:	Keith Tan
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca Time frame: past 36 months	Employment Funded the study Funded medical writing and project management support
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	☑ None □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	Other financial or non-financial	⊠ None	
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Kina Höglund
Manuscript Title:	MEDI1814 selectively reduces free A242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as neede	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planni	ng of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☑ None ☑	Click the tab key to add additional rows.
		Time frame: past 36 mo	nths
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None □ □ □ □ □ □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None □ □ □ □ □ □ □ □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None □ □ □ □ □ □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024
Your Name:	Maria T. Groves
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options Image: None			
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Mary McFarlane	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: Description of the initial planning AstraZeneca AstraZeneca AstraZeneca AstraZeneca AstraZeneca	of the work Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options Image: None			
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Michael Pomfret	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options Image: None			
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Michael S. Perkinton
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	Other financial or non-financial	⊠ None	
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Nicholas Kyle Proctor
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning Image: None Eli Lilly AstraZeneca AstraZeneca	of the work Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	D None	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024	
Your Name:	Per-Ola Freskgard	
Manuscript Title:	MEDI1814 selectively reduces free A242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	AD. J-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	 □ □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None AstraZeneca	a patent family that covers the composition of matter; and a medical use patent
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None □ □ □ □ □ □ □ □	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Image: None Image: I	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None □ □ □ □ □ □ □ □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None □ □ □ □ □ □	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024
Your Name:	Philip Newton
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Ratan V. Bhat
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	this item.		
		Time frame: past 36 months	S
2	Grants or contracts from	□ None	
	any entity (if not	AstraZeneca	Employee
	indicated in item #1 above).		
	,		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Richard Turner
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options D None			
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial None			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Susanna Eketjäll	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	c
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	Employee
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Susanne Gustavsson	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	this item.		
		Time frame: past 36 months	S
2	Grants or contracts from	□ None	
	any entity (if not	AstraZeneca	Employee
	indicated in item #1 above).		
	,		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024	
Your Name:	Tharani Chessell	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
	charges, etc.) No time limit for this item.		
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not	None AstraZeneca	Employee
	indicated in item #1 above).		
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	11 Stock or stock options Image: Stock option stock o		
		AstraZeneca	Shares/options
12	Receipt of equipment,	□ None	
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13	non-financial		
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Thor Ostenfeld
Manuscript Title:	MEDI1814 selectively reduces free A242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11 Stock or stock options None			
		AstraZeneca	Shares/options
12	Receipt of equipment,		
	materials, drugs,	AstraZeneca	Medical Writing Support
	medical writing, gifts or other		
	services		
13 Other financial or non-financial			
	interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	7/10/2024
Your Name:	Tristan J. Vaughan
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None AstraZeneca	Shares/options
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024
Your Name:	Yingdong Feng
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients
Manuscript Number (if known):	ADJ-D-24-00526R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Eli Lilly AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Eli Lilly	Employee
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support
13	Other financial or non-financial interests	⊠ None	
Plea	Please place an "X" next to the following statement to indicate your agreement:		

Date:	7/10/2024	
Your Name:	Zulma Santisteban Valencia	
Manuscript Title:	MEDI1814 selectively reduces free AI242 in cerebrospinal fluid of non-clinical species and Alzheimer's Disease patients	
Manuscript Number (if known):	ADJ-D-24-00526R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None AstraZeneca AstraZeneca AstraZeneca	Employment Funded the study Funded medical writing and project management support		
		Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None AstraZeneca	Employee		
3	Royalties or licenses	None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☑ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None	
6	Payment for expert testimony	⊠ None □	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None □ □ □ □ □ □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None AstraZeneca	Shares/options	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None AstraZeneca	Medical Writing Support	
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement:				